Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue , 1996, Pages 24-38

  Frydman, Armand ^a  

^a SANOFI   (France)

Author keywords

Absorption; Clinical pharmacology; Disposition profile; Distribution; Excretion; Low molecular weight heparins; Metabolism; Risk factors

Indexed keywords

ARDEPARIN; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOEMBOLEX; NADROPARIN; REVIPARIN; TINZAPARIN; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG METABOLISM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOSIS;

AGED; ANIMALS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; INTESTINAL ABSORPTION; PREGNANCY; TISSUE DISTRIBUTION;

EID: 0029921343     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217270     Document Type: Article

References (77)

1. McLean J: The Ihromboplastie action ofcephalin. Am J Physiol 1916; 41:250-257.
2. McLean J: The discovery of heparin. Circulation 1959;19:75-78.
3. Best CH: Preparation of heparin and its use in the first clinical cases. Circulation 1959:19:79-86.
4. Howell WH: Heparin, an anticoagulant: Preliminary communication. Am J Physiol 1992;63:434-435.
5. Best CH. Cowan C. MacLean DL: Heparin and the formation of white thrombi. J Physiol 1938;92:20-30.
6. Jaques LB, Charles AF, Best CH: The administration of heparin. Acta Med Scand Suppl 1938:90:190-207.
7. Best CH: Heparin and thrombosis. Br Med J 1938;vol ii:977-982.
8. Best CH. Jaques LB: Heparin in blood clotting and thrombosis. Ann NY Acad Sci 1948;49:501-517.
9. Bigelow WG: Mysterious Heparin, the Key to Open Heart Surge 17. Toronto. McGraw-Hill Ryerson, 1990.
10. Jaques LB: Heparin: A challenging enigma. J Orthomol Med 1990:8: 139-144.
11. Johnson EA, Kirkwood TBL, Stirling Y, Perez-Requejo JL, Ingram CIC, Banghum DR, Brozovic M: Four heparin preparations: Anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976;35:586-591.
12. Andcrsson LO, Barrowcliffc TW, Ilolmer E, Johnson EA, Sims GEC: Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin 111 and by gel filtration. Thromb Res 1976;9:575-583.
13. Fareed J. Walenga JM, Hoppen-steadt D, Huan X, Nonn R: Biochemical and pharmacological inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989; 556:333-353.
14. Vcrstraete M: Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 1990;40:498-530.
15. Hirsh J. Levine MN: Low molecular weight heparin. Blood 1992:79:1-17.
16. Hirsh J: Low molecular weight heparin. Thromb Haemost 1993;70: 204-207.
17. Green D. Hirsh J. Heit J. Prins M, Davidson B, Lensing AWA: Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev 1994;46:89-109.
18. Jaques LB, Wicc SM, Hieberl LM: Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities. J Lab Clin Med 1990:115:422-432.
19. Verstraete M, Wessler S: Heparin and anticoagulants; in Verstraete M, Fuster V (eds): Thrombosis in Cardiovascular Disorders. Philadelphia, Saunders, 1992, pp 121-140.
20. Hirsh J: Optimal therapeutic ranges from unfractionated heparin and low molecular weight heparins: in Verstraete M, Fuster V (eds): Thrombosis in Cardiovascular Disorders. Philadelphia. Saunders, 1992, pp 147-160.
21. Harenbcrg J. Wurzncr BN, Zimmer-mann R, Schettler G: Bioavailability and antagonizaton of the low molecular weight heparin CY216 in man. Thromb Res 1986;44:549-554.
22. Bratt G, Tornbohm E, Widlund L. Lockner D: Low molecular weight heparins (Kabi 2165, Fragmin''): Pharmacokinetics after intravenous and subcutaneous administration. Thromb Res 1986:42:613-620.
23. Dawes J. Bara L. Billaud E, Samama MM: Relation between biological activity and concentration of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16:116-122.
24. Frydman A. Bara L, Le Roux Y, Wolcr M, Chauliac F, Samama MM: The antithrombotic activity and pharmacokinetics of enoxapar-in. a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988:28:609-618.
25. Eriksson BE. Soedeberg K, Widlund L. Wandeli B. Tengborn L. Risbcrg B: A comparative study of three low molecular weight heparins(LMWH) and unfractionated heparin (UFH) in healthy volunteers. Thromb Hac-most 1993:69:6: 656 AB:410.
26. 11 a new low molecular weight heparin in healthy volunteers. Thromb Res 1994;73:95-108.
27. Collignon F, Dame B. Caplain H. Huet Y, Thebault JJ, Frydman A: Pharmacokinetics of enoxaparin in man given single subcutaneous doses of 1.0-1.25-1.50-2.0 mg/ kg. Thromb Res 1992;65:157.
28. Emanuele RM. Farced J: The effect of molecular weight on the bioavailability of heparin. Thromb Res 1987:48:591-596.
29. Swart de CAM, Nijmcyer B. An-dersson LO. Holmer O. Verschoon L, Bouma BN. Sixma JJ: Elimination of high affinity heparin fractions and their anticoagulant and lipase activity. Blood 1984:63:842-846.
30. Nishiyama M, Matubara Y. Ikeda S, Ueda T. llori K, Esumi Y: Studies on the metabolic fate of low' molecular weight heparin (FR-860): 1. Metabolic fate in rats. lyakuhin Kenkyu 1989:20:1056-1079.
31. Laforesl MD, Colas Linhart N, Gui-raud-Vitaux F. Bok B. Bara L. Samama MM, Marin J. Imbault F. Uzan A: Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. Br J Haematol 1991;77:201-208.
32. 99mTc) heparin and low molecular weigh heparin fractions CY 216. CY 222 in patients with uncomplicated myocardial infarction. Folia Haematol (Leipz) 1988:115:661-668.
33. Esquerre JP, Boneu B, Guiraud R: Kinetics of technetium-labelled heparin in thromboembolism: Preliminary report. In J Nucl Med 1979:6: 215-220.
34. Friedel HA. Balfour JA: Tinzaparin: A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 1994:48:638-660.
35. Collignon F, Frydman A. Caplain H, Bouthier J. Thebault JJ: Comparative pharmacokinetics of enoxaparin [Clexane®, Lovenox®] Kabi 2165 (Fragmin®) and CY 216 (Fraxipar-in®) in man (abstract 814). Thromb Haemost 1991;65:925.
36. Collignon F. Frydman A, Caplain H, Ozoux ML. Le Roux Y. Bouthier J, Thebault JJ: Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dal-teparin, enoxaparin and nadroparin-administered subcutanously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995:73:630-640.
37. Jaques I.B, Hicbcrt LM: The close relationship of heparin and the vessel wall. Artery 1989:16:140-150.
38. Marcum J A, Rosenberg RD: Role of endothelial cell surface heparin-like polysaccharides. Ann NY Acad Sci 1989:556:81-94.
39. Hiebert LM. Jaques LB: The observation of heparin on endothelium after injection. Thromb Res 1976;8: 195-204.
40. Dawes J. Pepper DS: Catabolism of low-dose heparin in man. Thromb Res 1986:43:1-6.
41. Boneu B. Caranobe C, Sic P: Pharmacokinetics of heparin and low molecular heparin. Baillieres Clin Haematol 190:3:531-544.
42. Kandrotas R: Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-374.
43. Brindley CJ, Taylor T, Dincss V: Relationship between pharmacokinetics and pharmacodynamics of tinzaparin (Logiparin"'), a low molecular weight heparin, in dogs. Xc-nobiotica 1993:23:575-588.
44. Rostin M, Montastruc JL. Houin G. D’Azomar PD. Bayrou B. Boneu B: Pharmacodynamics of CY2I6 in healthy volunteers: Inter-individual variations. Fundam Clin Pharmacol 1990:4:17-23.
45. Lockner D, Bratt G. Tomcbohm E, Aberg W. Granqvist S: Intravenous and subcutaneous administration of Fragmin® in deep venous thrombosis. Haemostasis 1986; 16(suppl 2): 25-29.
46. Simonneau G, Bergmann JF. Khcr A. Soria C, Tobelem G: Pharmacokinetics of a low molecular weight heparin (Fragmin®) in young and elderly subjects. Thromb Res 1992; 66:603-607.
47. Th6ry C. Simonneau G, Meyer G, Helenon O. Bridey F: Randomized trial of subcutaneous low molecular weight heparin CY 216 (Fraxipar-inc®) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism: A dose-ranging study. Circulation 1992:85:1380-1389.
48. Hoppenstcadi D, Breddin K. Fareed J. Walenga JM, Bender N: Relevance of anti-Xa, anti-lla and other laboratory parameters to the clinical efficacy of Fraxiparin *: Preliminary’ results of European FraxipariiT study (abstract 220). Haemostasis 1988:18(suppl 2): 164-165.
49. Poggliani EM. Bucciarelli P. Brcg-nani R. Chinea B, Longatti S: Eficct on haemostasis of repeated subcutaneous administration of CY 216 in volunteers (abstract 2410). Thromb Haemost 1991;65:1358.
50. Harenbcrg J. Huck K, Bratsch H. Wiirzner B, Zimmermann R. Schettler G: Therapeutic application of subcutaneous low-molecular-weight heparin in acute vein thrombosis. Haemostaseologie 1990;20: 205-209.
51. Barradell LB. Buckley MM: Nadroparin calcium: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992:33:858-888.
52. Johnston RV, Orr M. Rumley A, McLachlan J, Forbes CD: A study of the anti-thrombotic potential of low molecular weight heparin LHN-1 Novo in normal volunteers (abstract). Thromb Haemost 1987;58: 119.
53. Matzsch T. Bergqvisl D, Fredin H, Hedncr U, Ostcrgaard P: Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery. Thromb Res 1989;56:559-564.
54. Siegbahn A, Y-Hassan S, Boberg J, Bylund H, Neestrand HS, Oster-gaard P, Hcdner U: Subcutaneous treatment of deep venous thrombosis with low molecular weight heparin: A dose finding study with LMWU-Novo. Thromb Res 1989; 55:767-778.
55. Collignon F, Ozoux ML. Frydman A, Caplain H, Le Roux Y. Kaplan P, Thebault J J, Bouthier J: Comparative pharmacokinetics of enoxapar-in (Lovenox®, Clexane®) (30 mg bid) and unfractionatcd heparin (5,000 U tid) during repeated subcutaneous administration in man (abstract 1139). Thromb Haemost 1993:69:859.
56. Fejgin MD. Lourwood DL: Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv 1994:49:424-431.
57. Barrowcliffc TW, Johnson EA, Thomas DP: Clinical studies in prophylaxis of thrombosis; in Low Molecular Weight Heparin. Chichester. Wiley 1992, p 176.
58. Teien AN: Heparin elimination in patients with liver cirrhosis. Thromb Haemost 1977:38:701-708.
59. Simon TL, Myers TM, Gaston JP. Marker LA: Heparin pharmacokinetics: Increased requirements in pulmonary embolism. Br J Haematol 1978:39:111-120.
60. Goudable C, Saivin S. Houin G. Sie P. Boneu B, Tonthat H, Sue JM: Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron 1991;59:543-545.
61. Ozawa T, Hirokawa S, Alavapati R; McDonald FD, Mammen EF: Pharmacodynamics and pharmacokinetics of LMW heparin in normal subjects and patients with chronic renal insufficiency (abstact 1149). Thromb Haemost 1993:69:861.
62. Parker V, McDonald F, Mammen E, Troy S, Holloway S, C'hiang S: The effects of renal disease on arde-parin sodium pharmacodynamics (abstract PI 1-48). Clin Pharmacol Ther 1993:53:182.
63. Follea G, Laville M, Pozct N, De-chavannc M: Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with renal failure. Haemostasis 1986;16:147-151.
64. Aiach M, Michaud A, Balian JL, Le-febvre M, Woler M, Fourtillan J: A new low molecular weight heparin derivative: In vitro and in vivo studies. Thromb Res 1983:31:611-621.
65. Cadroy Y. Pourrat J. Baladre MF. Saivin S, Houin G, Monlastruc JL. Vernier I, Boneu B: Delayed elimination of enoxaparine in patients with chronic renal insufficiency. Thromb Res 1991;63:395-390.
66. Hirsh J, Levine MN: Low molecular weight heparin. Blood 1992;79:1-17.
67. Bara L, Samama M: Pharmacokinetics of low molecular weight heparins. Acta Chir Scand Suppl 1988; 543:65-72.
68. Hull RD. Pineo GF: Therapeutic use of low molecular weight heparins. Haemostasis 1993;23(suppl 1): 2-9.
69. Wolf W: Low' molecular weight heparin. Med Clin North Am 1994:78: 733-743.
70. Mason EC: A note on the use of heparin in blood transfusion. J Lab Clin Med 1924;10:203-206.
71. Hcdenius P, Wilander O: The influence of intravenous injections of heparin in man on the time of coagulation. Acta Med Scand 1936:88: 443-449.
72. Duclos JP: L’heparine: Fabrication. Structure. Proprietes, Analyses. Paris, Masson, 1984.
73. Padilla A, Gray E. Pepper DS, Barrowcliffc TW: Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992:82:406-413.
74. Bara L, Billaud E, Gramond G. Kher A, Samama M: Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985:39:631-636.
75. Buckley MM, Sorkin EM: Enoxa-parin: A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992; 44:465-497.
76. Freedman MD, Leese P, Prasad R, Hayden D: An evaluation of the biological response to Fraxiparine (a low molecular weight heparin) in the healthy individual. J Clin Pharmacol 1990:30:720-727.
77. Pedersen PC. Ostergaard PB. Hed-ner U, Bergqvist D, Matzsch T: Pharmacokinetics of a low molecular weight heparin. Logiparin. after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991;61:477-487.